Elucidating the prognostic and therapeutic significance of TOP2A in various malignancies

IF 1.4 4区医学 Q4 GENETICS & HEREDITY Cancer Genetics Pub Date : 2024-10-18 DOI:10.1016/j.cancergen.2024.10.005

Guangchao Liu , Wenlong Lin , Kaifeng Zhang , Kangxu Chen , Guanglin Niu , Yonghao Zhu , Yixuan Liu , Pengkun Li , Zhihao Li , Yang An

{"title":"Elucidating the prognostic and therapeutic significance of TOP2A in various malignancies","authors":"Guangchao Liu , Wenlong Lin , Kaifeng Zhang , Kangxu Chen , Guanglin Niu , Yonghao Zhu , Yixuan Liu , Pengkun Li , Zhihao Li , Yang An","doi":"10.1016/j.cancergen.2024.10.005","DOIUrl":null,"url":null,"abstract":"<div><div>Topoisomerase IIα (TOP2A) is a crucial enzyme that plays a vital role in DNA replication and transcription mechanisms. Dysregulated expression of TOP2A has been associated with various malignancies, including hepatocellular carcinoma, prostate cancer, colon cancer, lung cancer and breast cancer. In this review, we summarized the prognostic relevances of TOP2A in various types of cancer. The increased expression of TOP2A has been linked to resistance to therapy and reduced survival rates. Therefore, evaluating TOP2A levels could assist in identifying patients who may derive advantages from molecular targeted therapy. The amplification of <em>TOP2A</em> has been linked to a positive response to chemotherapy regimens that contain anthracycline. Nevertheless, the overexpression of TOP2A also indicates a heightened likelihood of disease recurrence and unfavorable prognosis. The prognostic significance of TOP2A has been extensively studied in various types of cancer. The increased expression of TOP2A is associated with poor clinical outcomes, indicating its potential as a valuable biomarker for assessing risk and stratifying treatment in these malignancies. However, further investigation is needed to elucidate the underlying mechanisms by which TOP2A influences cancer progression and to explore its potential as a therapeutic target.</div></div>","PeriodicalId":49225,"journal":{"name":"Cancer Genetics","volume":"288 ","pages":"Pages 68-81"},"PeriodicalIF":1.4000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genetics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210776224001297","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Topoisomerase IIα (TOP2A) is a crucial enzyme that plays a vital role in DNA replication and transcription mechanisms. Dysregulated expression of TOP2A has been associated with various malignancies, including hepatocellular carcinoma, prostate cancer, colon cancer, lung cancer and breast cancer. In this review, we summarized the prognostic relevances of TOP2A in various types of cancer. The increased expression of TOP2A has been linked to resistance to therapy and reduced survival rates. Therefore, evaluating TOP2A levels could assist in identifying patients who may derive advantages from molecular targeted therapy. The amplification of TOP2A has been linked to a positive response to chemotherapy regimens that contain anthracycline. Nevertheless, the overexpression of TOP2A also indicates a heightened likelihood of disease recurrence and unfavorable prognosis. The prognostic significance of TOP2A has been extensively studied in various types of cancer. The increased expression of TOP2A is associated with poor clinical outcomes, indicating its potential as a valuable biomarker for assessing risk and stratifying treatment in these malignancies. However, further investigation is needed to elucidate the underlying mechanisms by which TOP2A influences cancer progression and to explore its potential as a therapeutic target.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阐明 TOP2A 在各种恶性肿瘤中的预后和治疗意义。

拓扑异构酶 IIα （TOP2A）是一种关键酶，在 DNA 复制和转录机制中发挥着重要作用。TOP2A 的表达失调与多种恶性肿瘤有关，包括肝细胞癌、前列腺癌、结肠癌、肺癌和乳腺癌。在这篇综述中，我们总结了 TOP2A 在各类癌症中的预后相关性。TOP2A 的表达增加与耐药性和生存率降低有关。因此，评估 TOP2A 水平有助于确定哪些患者可从分子靶向治疗中获益。TOP2A 的扩增与对含有蒽环类药物的化疗方案的积极反应有关。然而，TOP2A 的过表达也表明疾病复发和预后不良的可能性增加。关于 TOP2A 在各类癌症中的预后意义，已经进行了广泛的研究。TOP2A 的表达增加与临床预后不良有关，这表明它有可能成为评估这些恶性肿瘤风险和分层治疗的重要生物标志物。然而，要阐明 TOP2A 影响癌症进展的内在机制并探索其作为治疗靶点的潜力，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Genetics ONCOLOGY-GENETICS & HEREDITY

CiteScore

3.20

自引率

5.30%

发文量

167

审稿时长

27 days

期刊介绍： The aim of Cancer Genetics is to publish high quality scientific papers on the cellular, genetic and molecular aspects of cancer, including cancer predisposition and clinical diagnostic applications. Specific areas of interest include descriptions of new chromosomal, molecular or epigenetic alterations in benign and malignant diseases; novel laboratory approaches for identification and characterization of chromosomal rearrangements or genomic alterations in cancer cells; correlation of genetic changes with pathology and clinical presentation; and the molecular genetics of cancer predisposition. To reach a basic science and clinical multidisciplinary audience, we welcome original full-length articles, reviews, meeting summaries, brief reports, and letters to the editor.